Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ

Whether malignant mesothelioma has an in situ phase has long been a controversy [1]. Until recently the consensus was that mesothelioma in situ (MIS) cannot be separated from reactive surface mesothelial proliferations on morphology alone. However, the concept of MIS was recently reintroduced for surface, usually flat or simple papillary, mesothelial proliferations with loss of BAP1 nuclear staining by immunohistochemistry occurring in patients with unexplained recurrent effusions in the absence of radiologic or clinical gross evidence of the disease [2 –4].

Source: Lung Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Sanja Dacic, Somak Roy, Maureen A. Lyons, Jan H. von der Thusen, Francoise Galateau-Salle, Andrew Churg Source Type: research